Safety Study of E303 Drug in Advanced Solid Tumors
Part of Cancer clinical trials.
This early-stage trial tests whether a new drug called E303 is safe for patients with advanced solid cancers (tumors that have spread or returned). Researchers want to find the right dose and watch for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Cancer must be a solid tumor (not blood cancer) that is advanced or has spread to other parts of the body
- Cancer must have come back after treatment, gotten worse during treatment, or standard treatments don't work or aren't available for you
- Cancer cannot have spread to the brain or spinal cord in certain ways
- You cannot have active blood clots, significant bleeding problems, or serious heart disease
- You cannot have an active autoimmune disease (where your immune system attacks your own body)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called JYP0035 alone in people with advanced solid tumors. It aims to see if the drug is safe and effective.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.